Sign Out
No adverse effects were observed in animal studies at exposures up to 300-fold higher than those in patients treated with Evolocumab (Repatha) at 420 mg once monthly.
There is no specific treatment for Evolocumab (Repatha) overdose. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.
Continue with Google